Mylan Loses Bid To Overturn Insomnia Drug Patent
Generic drugmaker Mylan has lost its fight to invalidate two Neurim patents for an insomnia treatment, as a London appeals court found on Friday that there was nothing wrong with the...To view the full article, register now.
Already a subscriber? Click here to view full article